Seeking Alpha

More on Immunomedics (IMMU): FQ4 misses across the board. Revenue was down Y/Y, due primarily to...

More on Immunomedics (IMMU): FQ4 misses across the board. Revenue was down Y/Y, due primarily to the milestone payment received during the prior year period. Bottom line numbers also suffered from higher than anticipated R&D spending, particularly on further clinical development of its pancreatic cancer drug clivatuzumab.
Comments (1)
  • bsmith4018
    , contributor
    Comment (1) | Send Message
     
    This news was totally expected. I'm actually encouraged by the higher than expected cash balance. The important thing is future development of promising drugs.
    23 Aug 2012, 04:40 PM Reply Like
DJIA (DIA) S&P 500 (SPY)